Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,975 | $12,165 | $7,815 | $13,863 |
| - Cash | $5,906,802 | $6,064 | $4,644 | $3,707 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$5,899,827 | $6,100 | $3,171 | $10,157 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1,993 | -$2,270 | $0 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$1,993 | -$2,246 | -$2,149 | -$2,782 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.23 | -1.89 | -2.14 | -3.27 |
| % Growth | 34.9% | 11.7% | 34.6% | – |
| Operating Cash Flow | -$1,881 | -$1,671 | -$2,051 | -$2,250 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,881 | -$1,671 | -$2,051 | -$2,250 |